Xeptiva Therapeutics
Xeptiva Therapeutics is a clinical-stage biotech developing first-in-class therapeutic vaccines for chronic inflammatory conditions in companion animals (dogs, cats, horses), using a recombinant multi-target immunogen platform licensed from Institut Pasteur de Montevideo and targeting a 2026 regulatory approval.
- Company typePrivate
- Founded2021
- HeadquartersMontevideo, Uruguay
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Xeptiva Therapeutics does
Xeptiva Therapeutics is a clinical-stage biotechnology company founded in 2021 as a spin-off from Institut Pasteur de Montevideo, developing first-in-class therapeutic vaccines to treat chronic inflammatory conditions in companion animals. The company's proprietary technology platform is built on recombinant multi-target immunogens based on Multiple Isomeric Epitopes, which elicit neutralizing antibodies against endogenous inflammatory mediators involved in neurogenic inflammation. Lead assets include Xep01, a therapeutic vaccine for canine osteoarthritis chronic pain built on rNGFSP technology, and Xep02, a vaccine for canine atopic dermatitis, both currently in clinical trials in Uruguay. The pipeline extends to equine chronic pain, feline chronic pain, and canine obesity vaccines, representing a multi-indication platform spanning the largest chronic-disease categories in companion animals.
The company licenses its core technology from Institut Pasteur de Montevideo, with which it maintains a deep co-development relationship including the institute as a partner and shareholder. Xeptiva has produced its first GMP-quality vaccine batch (2024), secured ANII government grants covering mechanism validation, hiring, and international patent filings across LATAM, Asia, and Europe, and is targeting regulatory approval in 2026. Distribution is planned through a hybrid model combining direct sales to veterinary clinics (initially in Uruguay) and global licensing agreements with major animal-health biotech firms, targeting an estimated $5 billion pet chronic-condition market. The company has raised approximately $2.5 million in seed funding led by Zentynel Frontier Investments and has no commercial revenue at present, with the November 2025 partnership with Athos Therapeutics adding an AI-driven biomarker discovery layer through the AthosOmics.AI platform.
Xeptiva Therapeutics firmographics
Firmographics- Name
- Xeptiva Therapeutics
- Legal name
- Xeptiva Therapeutics LLC
- Website
- https://xeptiva.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Xeptiva Therapeutics is a clinical-stage biotech developing first-in-class therapeutic vaccines for chronic inflammatory conditions in companion animals (dogs, cats, horses), using a recombinant multi-target immunogen platform licensed from Institut Pasteur de Montevideo and targeting a 2026 regulatory approval.
- Ownership category
- akta.pro rank
Xeptiva Therapeutics industry classification
Industry- Product category
- Veterinary Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Veterinary Vaccines (Biologics) (HLAMAEAL)
- akta.pro secondary industries
- Companion Animal Vaccines (Dogs & Cats) (HLAMAKAA), Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA) (HLAMAKAH)
Keywords
Where Xeptiva Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Montevideo
- HQ country
- Uruguay
- HQ region
- Latin America
Offices1 record
Markets served
Xeptiva Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Revenue model
- Therapeutic Vaccine Products: Xeptiva develops therapeutic vaccines for companion animals targeting chronic conditions. Revenue will be generated through product sales of vaccines like Xep01 (osteoarthritis) and Xep02 (atopic dermatitis) once regulatory approval is obtained. The company aims for international market expansion with a focus on the estimated $5 billion pet healthcare market.
- Licensing Agreements: Xeptiva is in discussions for licensing agreements with major biotech firms to bring its products to market. The company holds technology licensed from Institut Pasteur de Montevideo and is seeking partnerships for commercialization.
- Technology Licensing: The company signed a licensing agreement with Institut Pasteur de Montevideo to work with technology patented and generated at the institute to transform it into a marketable product.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
Xeptiva Therapeutics product offering
Product offeringCore offering
Xeptiva Therapeutics develops first-in-class therapeutic vaccines for companion animals targeting chronic inflammatory conditions, including canine osteoarthritis (Xep01) and atopic dermatitis (Xep02). The vaccines are based on proprietary recombinant multi-target immunogens using Multiple Isomeric Epitopes that elicit neutralizing antibodies against endogenous inflammatory mediators, offering a long-lasting alternative to daily medications.
Product overview
Xeptiva Therapeutics is a clinical-stage biotech company developing first-in-class therapeutic vaccines to treat chronic inflammatory conditions in companion animals. The company leverages recombinant multi-target immunogens based on Multiple Isamelic Epitopes targeting neurogenic inflammation. The core product portfolio includes Xep01 (dog osteoarthritis chronic pain vaccine) and Xep02 (dog atopic dermatitis vaccine), both in clinical trial phases. The pipeline extends to horse chronic pain, feline chronic pain, and dog obesity vaccines, representing a platform of immunotherapies targeting the most prevalent chronic conditions in pets, addressing an estimated $5 billion market.
Differentiator
Problem solved
Functional benefit
Products and services
- Xep01 Therapeutic vaccine for the treatment of chronic pain associated with canine osteoarthritis, stimulating antibody production to decrease pain and inflammation in vaccinated dogs.
- Xep02 Therapeutic vaccine designed for treatment of canine atopic dermatitis, a chronic condition causing intense itching, inflammation, and skin discomfort in dogs. Offers long-lasting action with potential to reduce or eliminate need for daily medication.
- Horse Chronic Pain Vaccine First-in-class immunotherapy targeting neuroinflammatory mediators for long-term pain control in equine patients with osteoarthritis. In development with placebo-controlled clinical trials planned for 2026.
- Feline Chronic Pain Vaccine Next-generation immunotherapy targeting key mediators of chronic pain (NGF and Substance P) to disrupt neuroinflammatory cascade in cats with osteoarthritis. Validation planned for 2026.
- Dog Obesity Vaccine
Quantifiable outcome
- Up to 80% of dogs over 9-10 years may suffer from chronic osteoarthritis pain
- +2 more outcomes
Companies that use Xeptiva Therapeutics
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Xeptiva Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature3 records
Xeptiva Therapeutics partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and supporting.
- Athos TherapeuticscorePartnership to utilize the AthosOmics.AI platform for analyzing omics data from clinical trial plasma samples of canines to identify biomarkers related to Xeptiva's therapeutic vaccine for osteoarthritis chronic pain. The collaboration aims to support the development of veterinary precision medicine using AI-driven analysis of omics data.
- Institut Pasteur de MontevideocoreStrategic partnership for development of technology. Institut Pasteur de Montevideo is a founding partner, having co-developed the core technology with Xeptiva's founders. The institution provides research facilities, scientific expertise, and has become a shareholder in the company.
- ATGENsupportingIndustrial partner fundamental in advancing vaccine projects, involved in the production of the first GMP-quality vaccine batch.
- Merck ArgentinasupportingIndustrial partner (Merck Argentina) collaborating in vaccine development and production, contributing to the first GMP-quality vaccine manufacturing.
Scale indicators4 records
Recent moves8 records
Expansion highlights6 records
Xeptiva Therapeutics competitors and assessment
Company assessmentBroad incumbents
- Virbac: Global animal health company with a companion animal portfolio spanning dermatology, pain management, and vaccines. Directly comparable as a mid-sized incumbent player in the same chronic-condition therapeutic categories Xeptiva targets.
- Zoetis: The world's largest animal health company, with leading franchises in companion animal pain (Librela), dermatology (Cytopoint, Apoquel), and vaccines. Overlaps with Xeptiva as the dominant incumbent Xeptiva's therapeutic vaccines would compete against for canine OA and atopic dermatitis.
- Phibro Animal Health: Diversified animal health and nutrition company with companion animal product lines. Comparable as a public-market reference point for smaller animal-health specialty players.
- Dechra Pharmaceuticals: Specialty animal health company with strong franchises in companion animal endocrinology, dermatology, and pain management. Recently acquired by EQT, providing a comparable specialty-pharma-style comparator for Xeptiva.
- Elanco Animal Health: Major global animal health company with strong positions in companion animal therapeutics, vaccines, and dermatology. Through acquisitions of Aratana Therapeutics and Kindred Biosciences, Elanco has built a pipeline of innovative pet biologics directly comparable to Xeptiva's strategic positioning.
- Vetoquinol: Independent global animal health company with companion animal pain, dermatology, and vaccine offerings. A relevant mid-cap incumbent peer for benchmarking Xeptiva's commercial opportunity.
- Boehringer Ingelheim Animal Health: Top-3 global animal health company with broad companion animal therapeutics and vaccine portfolios. A credible incumbent competitor and potential licensing partner for Xeptiva's technology.
Emerging players
- Aratana Therapeutics: Pioneering pet therapeutics biotech that developed innovative biologics for canine OA and other conditions before being acquired by Elanco. Provides a relevant historical template for a clinical-stage companion animal therapeutics company pursuing licensing/exit pathways.
- Kindred Biosciences: Was a clinical-stage biopharmaceutical company developing novel biologics for companion animals, including therapies for atopic dermatitis and pain. Acquired by Elanco in 2021 — another direct comparable to Xeptiva's development-stage strategy and exit archetype.
- Nexvet Biopharma: Pre-acquisition, Nexvet was a clinical-stage biopharma developing monoclonal antibody therapies for companion animals — a closely analogous model to Xeptiva's biologics-for-pets approach. Acquired by Zoetis in 2017, illustrating the standard exit/licensing pathway Xeptiva is targeting.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Xeptiva Therapeutics social profiles
Digital presenceXeptiva Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Xeptiva Therapeutics leadership team
Management profileNumber of profiles
Profiles14 records
Xeptiva Therapeutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Xeptiva Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Xeptiva Therapeutics
What does Xeptiva Therapeutics do?
Xeptiva Therapeutics develops first-in-class therapeutic vaccines for companion animals targeting chronic inflammatory conditions, including canine osteoarthritis (Xep01) and atopic dermatitis (Xep02). The vaccines are based on proprietary recombinant multi-target immunogens using Multiple Isomeric Epitopes that elicit neutralizing antibodies against endogenous inflammatory mediators, offering a long-lasting alternative to daily medications.
Is Xeptiva Therapeutics a public or private company?
Xeptiva Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Xeptiva Therapeutics founded?
Xeptiva Therapeutics was founded in 2021. It employs 1 to 10 people.
Where is Xeptiva Therapeutics based?
Xeptiva Therapeutics is headquartered in Montevideo, Uruguay, in the Latin America region.
How does Xeptiva Therapeutics make money?
Three revenue lines are on record. Therapeutic Vaccine Products are the primary driver. The others are licensing Agreements and technology Licensing.
Who are Xeptiva Therapeutics's main competitors?
Broad incumbents on record are Virbac, Zoetis, Phibro Animal Health, Dechra Pharmaceuticals, Elanco Animal Health, Vetoquinol and Boehringer Ingelheim Animal Health. Emerging players are Aratana Therapeutics, Kindred Biosciences and Nexvet Biopharma.
Does Xeptiva Therapeutics have an API?
No public API is recorded for Xeptiva Therapeutics.
What industry is Xeptiva Therapeutics in?
Xeptiva Therapeutics's product category is Veterinary Biopharmaceuticals. Its primary akta.pro industry code is HLAMAEAL, Veterinary Vaccines (Biologics), with a secondary code of HLAMAKAA, Companion Animal Vaccines (Dogs & Cats). Its NAICS code is 325414 and its SIC code is 2836.